Our mission
Transform the lives of patients suffering from heart failure by developing technology
that enables physicians to deliver optimal cardiac pacing.
Our team
Allan Will
Bio
Mr. Will is an operating executive with extensive experience founding, funding, operating, and selling medical device companies. Prior to EBR Systems, he led the negotiation of Ardian’s acquisition by Medtronic for over $800 million. Will was also founding Managing Director at Split Rock Partners and a Partner at St. Paul Venture Capital. Previously, he was Founder, Chairman & CEO of The Foundry, co-founding 11 companies there including Ardian, Evalve (acquired by Abbott Laboratories for $450 million), and Concentric Medical (acquired by Stryker for $135 million). Earlier in his career, Will served as CEO of AneuRx, acquired by Medtronic, growing to over $150 million the year of launch. Prior to that, he was President & CEO of Devices for Vascular Intervention, growing the business to 550 employees, $100 million revenue run rate, and acquisition by Eli Lilly. Will holds more than 30 issued patents and earned his Master of Science in Management from MIT and Bachelor of Science in Zoology from the University of Maryland.
John McCutcheon
Bio
Mr. McCutcheon has over 40 years of sales, marketing, and general management experience in medical devices. McCutcheon started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical, and Ceterix Orthopaedics (acquired by Smith & Nephew). He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific), and LuMend (acquired by Johnson & Johnson). McCutcheon holds Bachelor of Arts degrees in Economics and Psychology from the University of California, Los Angeles, and a Master of Business Administration from the UCLA Anderson Graduate School of Management.
Gary W. Doherty
Bio
Mr. Doherty was appointed as Chief Financial Officer in September 2023 and brings over 30-years of experience across technology, healthcare and finance to the role. Mr. Doherty has a proven track record of developing high performing finance functions and medical device companies including his previous role as CFO of Acutus Medical (NASDAQ:AFIB), a medical technology company specializing in cardiac arrhythmia and atrial fibrillation treatment. Prior to this, he held key positions at Volcano Corporation (acquired by Philips) for 12 years. Doherty holds a Bachelor of Science degree in Business Administration and Finance, from the San Diego State University.
Madhuri Bhat
Bio
Ms. Bhat has over 25 years of experience in public affairs, public policy, clinical, quality, and regulatory roles in medical devices. She led several successful pivotal clinical trials and multiple registries and secured regulatory approvals and clearances in the US and internationally for Class II and III cardiovascular systems. Most recently, Bhat served as Consulting Vice-President RA/Clinical for companies in the reproductive, GI, neurological, urological, and cardiovascular domains such as Kyma Medical (acquired by Zoll) as the Founder/Principal of her own consulting company. Prior to that, Bhat was the VP of RA/QC at Barrx Medical (acquired by Covidien, then Medtronic), VP of RA/Clinical at Corventis (acquired by Medtronic), and she held management positions at Guidant and Abbott Vascular. Bhat is a book author on child advocacy and serves as visiting faculty at San Jose State University. She holds a Bachelor of Science in Biology from the University of Mumbai, a diploma in Mass Communications from Sophia Polytech, and a Master of Public Policy from Duke University.
Michael Hendricksen
Bio
Mr. Hendricksen has over 25 years of medical device product development and manufacturing experience. Prior to joining EBR Systems, Hendricksen served as Chief Operating Officer at Ceterix Orthopaedics where he led the development of the NOVOSTITCH Pro Meniscal Repair System. Ceterix was acquired in 2019 by Smith+Nephew at which time Hendricksen assumed the role of Site Leader, where he scaled and integrated operations not only for Ceterix but also for Tusker Medical, another Smith+Nephew acquisition. Before Ceterix, Hendricksen was Vice President of R&D at Foundry NewcoXI and served in engineering roles of increasing responsibility at Emphasys Medical, Cardica, and IDEO Product Development. Hendricksen is an inventor on over 80 issued patents, and he holds a Master of Science in Mechanical Engineering from Stanford University and a Bachelor of Science in Mechanical Engineering from Northwestern University.
Spencer H. Kubo, M.D.
Bio
Dr. Kubo joined EBR in January 2019 and holds the same position at Heart Leaflet Technologies, where he oversees clinical trials for a next-generation Transcatheter Aortic Valve Replacement (TAVR). Kubo's career also includes roles as Executive Director of Merck's Academic and Professional Affairs department, Professor of Medicine, Co-Director of Clinical Cardiology, and Medical Director of the Heart Failure-Heart Transplantation Program at the University of Minnesota. Renowned for his research in heart failure, he has published over 250 papers and abstracts. Kubo earned his undergraduate degree in biology from Dartmouth College and his MD from Cornell University Medical College. He is a Fellow of both the American College of Cardiology and the American Heart Association.
Andrew Shute
Bio
Mr. Shute has over 25 years of medical device experience and has led the successful commercialization of new technologies and products working in the corporate, start-up, and distributor settings. He brings a strong business, clinical training, and sales management background to the team, including positions at St. Jude Medical, Endocardial Solutions, and Getz Brothers. Shute received his Bachelor of Science from the University of Wollongong, Australia. Shute previously held the position of Chairman of the Cardiac Rhythm Management section of the Association of British Healthtech Industries Ltd (ABHI).
Erik Strandberg
Bio
Mr. Strandberg, with a B.S. in Finance from Florida State University and over two decades in the medical device sales industry, has demonstrated exceptional leadership in strategic planning and operational oversight. At AtriCure, as Senior Vice President of the Hybrid Therapies Division, he led sales and marketing efforts, leveraging relationships across the medical field to drive growth and market expansion. His career includes pivotal roles at Boston Scientific, St. Jude Medical, and Guidant Corporation, where he launched various cardiac therapies and led teams to substantial achievements. Strandberg's educational advancements through executive programs at the University of Texas and the Wharton School, coupled with his certification in healthcare finance and specialized cardiac device knowledge, underscore his strategic leadership and contributions to the industry.
N. Parker Willis, Ph.D.
Bio
Dr. Willis is an electrical engineer with extensive experience in signal processing applications and has worked in medical devices for over 20 years, all in technical leadership capacities for development of novel technologies for cardiac electrophysiology. He previously held senior positions at Boston Scientific and Cardiac Pathways. Willis is an inventor on more than 28 issued patents. He earned his Bachelor of Science in Electrical Engineering from the University of California, San Diego, and his Master of Science and Ph.D. from the University of Illinois Urbana-Champaign.
Allan Will
Bio
Mr. Will is an operating executive with extensive experience founding, funding, operating, and selling medical device companies. Prior to EBR Systems, he led the negotiation of Ardian’s acquisition by Medtronic for over $800 million. Will was also founding Managing Director at Split Rock Partners and a Partner at St. Paul Venture Capital. Previously, he was Founder, Chairman & CEO of The Foundry, co-founding 11 companies there including Ardian, Evalve (acquired by Abbott Laboratories for $450 million), and Concentric Medical (acquired by Stryker for $135 million). Earlier in his career, Will served as CEO of AneuRx, acquired by Medtronic, growing to over $150 million the year of launch. Prior to that, he was President & CEO of Devices for Vascular Intervention, growing the business to 550 employees, $100 million revenue run rate, and acquisition by Eli Lilly. Will holds more than 30 issued patents and earned his Master of Science in Management from MIT and Bachelor of Science in Zoology from the University of Maryland.
Karen Drexler
Bio
Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. She currently serves on the boards of two other public companies, ResMed, Inc. and Outset Medical Inc., focusing on the compensation, nominating, and governance committees. Drexler also serves on the boards of two private companies: VIDA Diagnostics Inc., an artificial intelligence-powered lung imaging solutions company, and Tivic Health Systems, Inc., a bioelectric medicine company focused on relief of congestion and sinus pain. She also acts as a senior strategic advisor for other early-stage companies and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Drexler is an active mentor and advisor to Astia, a global nonprofit that supports high-potential female founders, as well as a mentor with StartX, the Stanford University incubator. She graduated magna cum laude with a Bachelor of Science in Chemical Engineering from Princeton University and earned an MBA with Honors from the Stanford University Graduate School of Business.
Bronwyn Evans, Ph.D., A.M.
Bio
Dr. Evans is an experienced leader and CEO with a broad technical background across multiple industry sectors, including medical technology, manufacturing, power generation and distribution, and technical regulation and standards. Most recently she was the CEO of Engineers Australia, she also serves as the Chair of Building 4.0 CRC and as Director at GME Pty Ltd. Prior to her role with Engineers Australia, Evans was the CEO of Standards Australia. She has previously held positions in innovation initiatives, including Chair of MTPConnect (the Industry Growth Center for Medical Technologies and Pharmaceuticals) and was a member of the Industry 4.0 Advanced Manufacturing Forum Leadership group. Evans has been recognized as one of Australia’s 100 most influential engineers and as one of 100 Women of Influence. She holds a Bachelor of Engineering (Honors I) and a Ph.D. in Electrical Engineering from the University of Wollongong. Additionally, she holds an Honorary Doctorate from Swinburne University and is an Honorary Fellow of the University of Wollongong and Engineers Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering.
Trevor Moody
Bio
Mr. Moody has served as a Director of EBR since 2017. He served as Medical Device Partner at M.H. Carnegie & Co. (from October 2013 to April 2022), where he made investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Moody was previously a General Partner at Frazier Healthcare Ventures, a large U.S. based private equity and venture capital firm. Currently a Director of Cardiac Dimensions Pty Ltd., Renew Medical Pty Ltd., The Brain Protection Company Pty Ltd., and CurvaFix, Inc., Moody also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long-distance travel for medical treatment. He holds a B.Eng. from the University of Southern Queensland and an M.S. in Management from the Massachusetts Institute of Technology (Sloan School).
Christopher Nave, Ph.D.
Bio
Dr. Nave has served as a Director of EBR since 2017. He is a Founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialization Fund. Nave previously served as the Director of Commercialization at the Baker Heart Research Institute. Currently a Director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd., Global Kinetics Corporation Ltd., OccuRx Pty Ltd., Osprey Medical Inc., PolyActiva Pty Ltd., and Que Oncology, Inc. Nave was Chairperson of Fibrotech Therapeutics Pty Ltd. at the time of its successful sale to Shire Plc and a Director of Spinifex Pharmaceuticals, Inc. at the time of its sale to Novartis International AG. He holds a B.Sc. (Honors) and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and is a member of the Australian Investment Council.
David Steinhaus, M.D.
Bio
Dr. Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc. He joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. Steinhaus’ responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies, and medical groups. Closely associated with research and academia, performing extensive clinical studies in implantable cardiac devices and leads, he served as Chair of the Department of Cardiology and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke’s Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine. Since leaving Medtronic, he has served as a consultant and board member to multiple medical device companies. Currently the Executive Chairman of the board of Enopace Biomedical Ltd., a company that produces therapeutic neuromodulation devices for the treatment of heart failure, he graduated magna cum laude from Harvard College and received his medical doctorate from Harvard Medical School as part of the Harvard M.I.T. program in Health Sciences and Technology, with AOA honors.
John McCutcheon
Bio
Mr. McCutcheon has over 40 years of sales, marketing, and general management experience in medical devices. McCutcheon started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical, and Ceterix Orthopaedics (acquired by Smith & Nephew). He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific), and LuMend (acquired by Johnson & Johnson). McCutcheon holds Bachelor of Arts degrees in Economics and Psychology from the University of California, Los Angeles, and a Master of Business Administration from the UCLA Anderson Graduate School of Management.
Our Values
We prioritize the personal and professional growth of our team members and empower them to create the future of cardiac rhythm management.
Patients First
We place the needs of patient’s first in everything we do.
Positivity
We maintain a positive mindset that fosters trust, teamwork, and success.
Leadership
We believe leadership is an attitude, not just a role—everyone can contribute.
Expression
We encourage constructive debate and strive for continuous improvements.
Our story
At EBR, we are working to revolutionize cardiac rhythm management. Founded in Silicon Valley in 2003, the company focuses on blending clinical insights with technological ingenuity to overcome the limitations of conventional cardiac resynchronization therapy (CRT).
The WiSE technology introduces a leadless, versatile, and a physiologic approach to pacing the heart.
WiSE Milestones
2003
EBR founded
2011
First WiSE in human clinical trial initiated
2016
First implants in EU registry
2018
World's first totally leadless CRT implant
2019
Awarded FDA Breakthrough Device Designation
2020
World's first leadless conduction system implant
2023
WiSE System pivotal SOLVE-CRT trial stops early with positive interim results
CRM Milestones
1993
First in human lead
conventional CRT
2013
First in human
leadless Implant
2018
Conduction System Pacing emerges
2022
First leadless dual chamber implant
2023
HRS Guidelines Update: Cardiac Physiologic Pacing
Join our mission to reshape cardiac rhythm care
At EBR, your work directly impacts the evolution of cardiac rhythm management. As part of our skilled and expert team, you'll play a crucial role in advancing our WiSE CRT System — a pioneering medical device system set to redefine cardiac care. Located in Silicon Valley, we are in search of professionals who are motivated to solve challenging technological problems required to bring ground breaking medical devices to market.
Breakthrough product
Be part of the journey with a product that's the first of its kind.
Team-oriented culture
Grow in an environment that values teamwork, transparency, and collaboration.
Financial well-being
Competitive salaries, 401K plan, and stock options.
Work-life harmony
Generous PTO starting at 3 weeks per year.
Career growth
Many opportunities in our fast-growing startup environment.
Robust benefits package
Comprehensive medical, dental, vision, and life insurance.